PayPoint plc (LON:PAY – Get Free Report) insider Nick Wiles purchased 18 shares of the stock in a transaction dated Wednesday, January 22nd. The shares were acquired at an average cost of GBX 695 ($8.56) per share, with a total value of £125.10 ($154.01).
PayPoint Stock Performance
PayPoint stock opened at GBX 687 ($8.46) on Thursday. The stock has a market cap of £495.53 million, a PE ratio of 1,402.04, a P/E/G ratio of 31.13 and a beta of 0.93. The company has a quick ratio of 0.65, a current ratio of 0.99 and a debt-to-equity ratio of 81.52. PayPoint plc has a 12-month low of GBX 470 ($5.79) and a 12-month high of GBX 865 ($10.65). The business’s 50-day moving average price is GBX 774.04 and its two-hundred day moving average price is GBX 721.80.
PayPoint (LON:PAY – Get Free Report) last released its quarterly earnings data on Thursday, November 21st. The company reported GBX 27.80 ($0.34) earnings per share (EPS) for the quarter. PayPoint had a net margin of 11.98% and a return on equity of 30.65%. As a group, analysts expect that PayPoint plc will post 56.9500056 earnings per share for the current fiscal year.
PayPoint Increases Dividend
PayPoint Company Profile
PayPoint plc engages in the provision of payments and banking, shopping, and e-commerce services and products in the United Kingdom. The company operates through two segments: PayPoint and Love2shop. The PayPoint segment provides card payment services to retailers, including leased payment devices; EPoS; ATM cash machines; SIM cards sales; receipt advertising; bill payment services and cash top-ups to individual consumers; parcel delivery and collection services; retailer service fees solutions; and digital payment services, as well as cash through to digital services.
Read More
- Five stocks we like better than PayPoint
- How Technical Indicators Can Help You Find Oversold Stocks
- 2 ETFs to Maximize Gains With Covered Call Strategies
- Where Do I Find 52-Week Highs and Lows?
- 3 Small-Cap Stocks Insiders and Institutions Are Buying
- What is Put Option Volume?
- MaxCyte: Building the Future of Cell and Gene Therapy Innovation
Receive News & Ratings for PayPoint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PayPoint and related companies with MarketBeat.com's FREE daily email newsletter.